Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.55 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588406 | 0.87 | ACKR3 (0.51) | ACKR3TBK1 | |
| SCHEMBL8420482 | 0.87 | ACKR3 (0.50) | ACKR3TBK1CYP3A4CYP2D6 | |
| SCHEMBL13391188 | 0.85 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL13588425 | 0.84 | TBK1 (0.51) | TBK1CYP3A4 | |
| SCHEMBL13391205 | 0.84 | CYP3A4 (0.61) | CYP3A4CYP2D6MGLL | |
| SCHEMBL14624187 | 0.83 | ACKR3 (0.48) | ACKR3TBK1CYP3A4CYP2D6 | |
| SCHEMBL14469361 | 0.80 | TBK1 (0.47) | ACKR3TBK1 | |
| SCHEMBL14469631 | 0.79 | HRH1 (0.49) | TBK1 | |
| SCHEMBL13588416 | 0.79 | TBK1 (0.49) | TBK1 | |
| SCHEMBL14091145 | 0.79 | ACKR3 (0.49) | ACKR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | ACKR3 1116/4885TBK1 2533/4885CYP3A4 1140/4885 |
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | ACKR3 2293/4885TBK1 358/4885CYP3A4 2573/4885 |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | HRH2, HRH1, HRH4 | ACKR3 67/4885TBK1 638/4885CYP3A4 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.